Beizray Generic: When Will Generic Docetaxel Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Beizray Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? May 2036 About 9.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet
- When does the last patent end? May 2036 3 patents listed with the FDA
- Can you buy a generic today? Yes 18 companies list one
It already is. A generic docetaxel is listed for sale by 18 companies, so ask your pharmacy whether it can fill your prescription with one.
Why May 2036?
It is when Beizray’s patents 11,419,842, 12,090,134 and 12,090,135 end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Beizray, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Beizray by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2024 October 2024 FDA Orange Book
- Patents listed 3 last runs to May 2036 FDA Orange Book
Beizray’s Road to a Generic
Beizray has had the market to itself since the FDA approved it in October 2024 (Zhuhai Beihai Biotech Co Ltd). Its 3 listed patents run to May 2036.
The first generic of Beizray is expected in May 2036.
Why that month: patents 11,419,842, 12,090,134 and 12,090,135, on the product’s formulation and a way of using it, end then. That is a few months before the last listed patent runs out, in May 2036.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Beizray Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Beizray’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patents 11,419,842, 12,090,134 and 12,090,135, which end in May 2036, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 11,419,842 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-881, U-937, U-946, U-4027, U-4028) | May 2036 | Active |
| 12,090,134 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-881, U-937, U-946, U-4027, U-4028) | May 2036 | Active |
| 12,090,135 Sets the expected month of generic availability | The product’s formulation | May 2036 | Active |
Source: FDA Orange Book, application 218711. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Docetaxel
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Beizray yet.
Approved by the FDA
Not yet. The FDA has not approved a generic docetaxel. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Yes. A generic docetaxel is listed for sale by 18 companies. Ask your pharmacy whether it can fill your prescription with it.
Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Armas Pharmaceuticals Inc., AuroMedics Pharma LLC, Baxter Healthcare Corporation and 12 more
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Beizray Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Beizray, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
Beizray Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 80MG/4ML (20MG/ML) | Solution | Intravenous | October 2024 | Prescription reference product |
| 20MG/ML (20MG/ML) | Solution | Intravenous | December 2025 | Prescription reference product |
Source: FDA Orange Book, Zhuhai Beihai Biotech Co Ltd. Listed for sale today by Zydus Pharmaceuticals USA Inc. and Zhuhai Beihai Biotech Co., Ltd. (FDA NDC Directory).
Beizray NDC Codes and Packages
Each Beizray package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 70710-2092-08 | DOCETAXEL ANHYDROUS 20 mg/mL injection, solution | vial of 1 mL | Zydus Pharmaceuticals USA Inc. |
| 70710-2152-01 | DOCETAXEL ANHYDROUS 20 mg/mL injection, solution | vial of 4 mL | Zydus Pharmaceuticals USA Inc. |
| 83513-0008-01 | DOCETAXEL ANHYDROUS 20 mg/mL injection, solution | vial of 1 mL | Zhuhai Beihai Biotech Co., Ltd. |
| 83513-0009-01 | DOCETAXEL ANHYDROUS 20 mg/mL injection, solution | vial of 4 mL | Zhuhai Beihai Biotech Co., Ltd. |
| 70710-2091-03 | kit | 1 KIT in 1 KIT * 4 mL in 1 VIAL, GLASS * 50 mL in 1 VIAL, GLASS | Zydus Pharmaceuticals USA Inc. |
| 70710-2093-04 | kit | 1 KIT in 1 KIT * 4 mL in 1 VIAL, GLASS * 50 mL in 1 VIAL, GLASS * 4 mL in 1 VIAL, GLASS | Zydus Pharmaceuticals USA Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Beizray’s own FDA approval (NDA 218711) are listed, never a generic. Some codes belong to companies that repackage Beizray: it is the same medicine in a different package.
What a Generic Beizray Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Beizray
Is there a generic for Beizray right now?
Yes. The FDA NDC Directory lists a generic docetaxel from 18 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Beizray go generic?
It already has. The FDA NDC Directory lists a generic docetaxel from 18 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic docetaxel be the same as Beizray?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Beizray?
Not yet. The FDA Orange Book lists no approved generic version of Beizray.
When does the Beizray patent expire?
The FDA Orange Book lists 3 patents for Beizray; the last runs to May 2036. The one behind the expected month is patents 11,419,842, 12,090,134 and 12,090,135, which end in May 2036. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (May 2036) weighs all of that.
Changes to This Projection
- First generic expected May 2036 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- VarithenaPolidocanolMay 2032
- ImcivreeSetmelanotide AcetateJuly 2034
- RinvoqUpadacitinibApril 2037
- DanzitenNilotinib TartrateFebruary 2040
- NeuproRotigotineTBD no date yet
- ActharCorticotropinTBD no date yet
About Beizray
- Generic name docetaxel
- How it is taken Into a vein (IV)
- Company Zhuhai Beihai Biotech Co Ltd
- More drugs Brand-name drugs starting with B
- Have a question? A pharmacist answers, free. Ask about Beizray
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.